Vaccine for Fruit Allergy

Allergen immunotherapy may be an effective option for patients with food allergy, and vaccines play an increasingly important role in the prevention and control of allergic diseases. Creative Biolabs is a world leader in the field of vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services for allergic disease.

Background of Fruit Allergy

Fruit allergy is the most common food allergy in adolescents and adults. It is more frequently found in females and pollen-allergic subjects. In a systematic review, 2.2-11.5% of children aged 0-6 years and 0.4-6.6% of adults reported adverse reactions to fruits. To date, many fruit allergens have been identified and used for immunotherapy of allergic diseases. The most studied and most well-known allergens include Pru p3 of peach and Mal d1 of apple. Since the natural conformation of allergens can present IgE-reactive epitopes, they possess full allergenic potential and can induce allergic symptoms through mediator released from mast cells and basophils. Chemically modified allergen extracts (allergens) and hypoallergenic proteins with reduced IgE antibody-binding capacity are considered novel allergen vaccines to reduce the frequency of adverse reactions.

Vaccines for Peach Allergy

Peaches are the most common plant foods that cause food allergic reactions in the adult population from Northern Europe and the Mediterranean. The major peach allergen, named Pru p3, belongs to the lipid transfer protein (LTP) panallergen family which is important allergens not only in Rosaceae fruits but also in other plant foods, such as vegetables, cereals, and nuts. Peach allergy mediated by Pru p3 is related to mild reactions restricted to the oropharyngeal cavity (oral allergy syndrome, OAS). The hypoallergenic derivative-folding variants of Pru p 3 are identified by site-directed mutagenesis. They show a decrease in its IgE binding capacity, conserve IgG epitopes and retain the capacity to stimulate T cells, inducing similar cytokine profiles to the wild type allergy. Therefore, recombinant Pru p3 could be a potential vaccine candidate for peach allergy. In addition, the major T-cell epitopes of Pru p3 has also been characterized. The T cell epitope Pru p3_65-80 can activate different Th subtypes, and the characterization of T cell epitopes is of great significance for the future development of specific immunotherapy for type I allergy. Therefore, the T cell epitope Pru p3_65-80 is a good candidate for the development of a new vaccine that is hypersensitive to LTP allergen from Rosaceae fruits.

Vaccines for Apple Allergy

Apple allergy is a common food allergy phenomenon. Allergic reactions to apples are mainly associated with oral allergy syndrome (OAS), which is characterized by oropharyngeal symptoms, including itching, tingling, burning, and swelling of lips and tongue. Mal d 1 is one of the major allergens in apple and shares T cell and IgE-binding epitopes with major birch pollen allergen, Bet v1. The use of hypoallergenic mutants would be a good strategy to avoid the undesirable side effects of immunotherapy. The hypoallergenic form of Mal d1 can be produced by site-directed mutagenesis, where five amino acid residues are exchanged. These mutants have altered their capacity to bind IgE, but they still preserve the capacity to stimulate the immune system, inducing the proliferation of T lymphocytes and the production of specific blocking IgG antibodies which compete with IgE. Therefore, recombinant Mal d1 vaccine could be a potential therapeutic option for apple allergy.

Our Services for Vaccine of Fruit Allergy

Creative Biolabs has a variety of mature and comprehensive platforms and technologies for vaccine development, and we are committed to providing the best solutions and customized protocols for vaccine design and development for fruit allergy. We offer the following related services:

• Identification of allergens epitope in fruit
• Cloning, expression, purification, and sequencing of recombinant major allergens
• Evaluation and data analysis of the immune effects of candidate vaccine
• Provide specialized vaccine development designs and solutions based on customer needs

Creative Biolabs is a world leader in the field of vaccine development and has been dedicated to vaccine design services for many years. We have experienced experts and advanced platforms that are able to provide excellent vaccine design and development services for allergic disease. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.